SBIR Contract Solicitation (PHS 2022-1) for Small Businesses

Funding News Edition: August 18, 2021
See more articles in this edition

Small businesses are invited to submit research proposals in response to A Solicitation of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals published on July 30, 2021.

Proposals are due by October 28, 2021 at 5 p.m. Eastern Time.

If you missed the August 12 webinar about the solicitation, check for a video recording and webinar slides on NIH’s Engage & Connect webpage.

Note: This SBIR contract solicitation is separate from the recently issued 2021 SBIR and STTR Omnibus/Parent Grant Solicitations for the NIH, CDC, and FDA, which are funding opportunity announcements for grant awards (despite the word “solicitation” appearing in the titles). Learn more about those grant opportunities in the August 4, 2021 article “Explore Topics for 2021 Small Business Omnibus Grants.”

The table below offers a brief summary of each of NIAID’s research topics of interest for contract proposals. Refer to the attachment posted within the solicitation linked above for full details.

Topic Number and Title Project Goal Budget (Total Costs)

101. Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines

To develop an HIV vaccine platform for delivery of HIV envelope (Env) immunogens that induce broadly neutralizing antibodies (bNAbs) and demonstrate that the vaccine platform/immunogen proposed will elicit a strong and durable NAb HIV Env response.

Phase I: $300,000 for up to one year

Phase II: $2 million for up to three years

102. Genetically Engineered Mice for Preclinical Evaluation of HIV Vaccine Candidates

To utilize genetically engineered mouse models, such as human immunoglobulin knock-in or other transgenic mice expressing relevant human genes, to accelerate testing and development of HIV vaccine candidates.

Phase I: $300,000 for up to one year

Phase II: $2 million for up to three years

103. Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity

To support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced sero-positivity, with high sensitivity and specificity.

Phase I: $300,000 for up to one year

Phase II: $2 million for up to three years

104. Adjuvant Discovery for Vaccines and for Autoimmune and Allergic Diseases

To support the screening for new adjuvant candidates for vaccines against infectious diseases, or for autoimmune and allergic diseases, or transplantation; their characterization; and early-stage optimization.

Phase I: $300,000 each year for up to two years

Phase II: $1 million each year—with appropriate justification—for up to three years

105. Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases

To support the preclinical development of novel vaccine adjuvants for use in vaccines against infectious diseases or of tolerogenic adjuvants for the treatment of immune-mediated diseases.

Phase I: $300,000 each year for up to two years

Phase II: $1 million each year—with appropriate justification—for up to three years

106. Production of Adjuvants Mimics

To develop, validate, and produce adjuvants that are based on, or similar to, compounds or formulations previously successfully used in clinical trials, for use by the broader research community, either as commercial products or through licensing agreements.

Phase I: $300,000 each year for up to two years

Phase II: $1 million each year—with appropriate justification—for up to three years

107. Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models

To develop and validate reliable antibodies and reagents for identifying and tracking immune cells or the analysis of immune function/responses (e.g., cytokines, chemokines, intracellular signaling) in non-mammalian models or underrepresented mammalian models.

Phase I: $300,000 each year for up to two years

Phase II: $1.5 million—with appropriate justification—for up to three years

108. Development of Rapid Point-of-Care (POC) Diagnostics for Treponema pallidum

To develop a rapid (less than one hour), POC diagnostic capable of detecting Treponema pallidum directly from patient specimens.

Phase I: $300,000 each year for up to two years

Phase II: $1.5 million—with appropriate justification—for up to three years

109. Development of Monoclonal Antibody-Mediated Interventions To Combat Malaria

To develop monoclonal antibody (mAb) or mAb-based candidates for malaria prevention or treatment.

Phase I: $300,000 for up to two years

Phase II: $1.5 million for up to three years

110. POC Diagnostics for Antimicrobial Resistant (AMR) Enteric Bacterial and Parasitic Pathogens

To develop a rapid (less than one hour), POC diagnostic capable of detecting infectious enteric pathogens (two or more) and associated antimicrobial resistance profile(s) directly from patient specimens (e.g., stool samples).

Phase I: $300,000 for up to one year

Phase II: $1.5 million for up to three years

111. Data Science Tools for Infectious and Immune-Mediated Disease Research

To support the new development of innovative, robust informatics/data science tools, or enhancement or adaptation of existing tools for use in infectious, immune, and allergic diseases.

Phase I: $300,000 for up to one year

Phase II: $1 million for up to three years

112. Digital Tools Against Misinformation About Infectious Disease Treatments and Vaccines

To develop digital tools to identify and combat malicious digital bots that spread misinformation about infectious disease treatments and vaccines.

Phase I: $300,000 for up to one year

Phase II: $1 million for up to three years

Direct your technical questions about the solicitation and NIAID’s topics to Charles Jackson in NIAID’s Office of Acquisitions.  

You can also learn more about NIAID Small Business Programs, and contact Natalia Kruchinin for general funding questions.

Contact Us

Email us at deaweb@niaid.nih.gov for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on